Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jun 3;11:683951. doi: 10.3389/fonc.2021.683951

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Du, Miao, Jiang, Cao, Wang, Wang, Yu, Wang and Liu

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Significant correlation of CALU with multiple ICRGs. (A, B) CALU was positively correlated with CD274 (p<0.001, R=0.470), CTLA4 (p<0.001, R=0.360), HAVCR2 (p<0.001, R=0.540), LAG3 (p<0.001, R=0.390), PDCD1 (p<0.001, R=0.340), PDCD1LG2 (p<0.001, R=0.630), and TIGIT (p<0.001, R=0.360), while negatively correlated with SIGLEC15 (p<0.001, R=-0.360). (C) ICB therapy responsiveness predicted by Immunecell AI indicated a significantly higher response rate in CALU^high patients than in CALU^low patients(p<0.001). The CALU expression level in ICB responders was higher than that in non-responders (p<0.001). ***p<0.001.